Clinical trials: Multiple Sclerosis-Relapsing-Remitting
Relapsing-Remitting Multiple Sclerosis
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00391352
- Testing
- IFN-β-1a (Rebif®)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Waukesha Memorial Hospital
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS)…
- Trial name
- RELIEF (NCT02064816)
- Testing
- Rebif®
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Depression - Major Depressive Disorder
Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis
Canada has one of the highest rates of multiple sclerosis (MS). MS patients experience disabling motor, visual, and sensory symptoms, and a high risk of comorbid major depressive disorder (MDD) and severe fatigue.
- Conditions
- Multiple Sclerosis, Depression - Major Depressive Disorder, Fatigue
- Trial name
- NCT07562074
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
B-cells have an important role in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, a medication that targets B-cells have been found to be highly effective in stopping the disease activity in relapsing-remitting MS.
- Trial name
- NCT04261790
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
The purpose of this study is to determine whether melatonin is effective in the treatment of relapsing-remitting multiple sclerosis patients as a supplement to the main disease-modifying drugs.
- Trial name
- NCT01279876
- Testing
- Melatonin
- Where
- Iran
- Volunteers
- 25 people
- Sponsor
- Tehran University of Medical Sciences
Relapsing Remitting Multiple Sclerosis
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
- Trial name
- NCT02258217
- Testing
- Acthar
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- OhioHealth
Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost.
- Trial name
- DESIRE MS (NCT07189325)
- Testing
- Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
Phase IV open label, single-blind study, post-marketing, 1-year MRI observational study evaluating effect of Avonex® monotherapy (6.0 MIU administered i.m.
- Trial name
- NCT00463710
- Testing
- Avonex® monotherapy (6.0 MIU administered i.m. each week)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- State University of New York at Buffalo
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multicenter study conducted in 2 parts: The primary objective in Part I of this study is to determine the efficacy of BG00012 (dimethyl fumarate, DMF) on inflammatory brain magnetic resonance imaging (MRI) lesion…
- Trial name
- NCT01838668
- Testing
- dimethyl fumarate
- Where
- 54 sites in Czechia, Japan and 3 more
- Volunteers
- 225 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
- Trial name
- DreaMS (NCT01081782)
- Testing
- ONO-4641
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 407 people
- Sponsor
- Ono Pharma USA Inc
Multiple Sclerosis-Relapsing-Remitting
Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.
- Trial name
- IGLOO (NCT02137707)
- Testing
- Gilenya
- Where
- 6 sites in Canada
- Volunteers
- 135 people
- Sponsor
- McGill University
Multiple Sclerosis, Relapse
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
This is a multi-center, prospective, controlled study. MS patients (1° group: 30 patients in relapse; 2° group: 30 patients in remission) and age/sex-matched healthy controls (3° group: 30 subjects) will be enrolled in the study.
- Trial name
- NCT04380220
- Testing
- Blood samples and processing
- Where
- 3 sites in United States, Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Relapsing Remitting Multiple Sclerosis
Intermittent Fasting in Multiple Sclerosis
This is a randomized controlled trial that will test the effects of intermittent fasting (IF) in subjects with relapsing-remitting MS (RRMS).
- Trial name
- IFMS (NCT03539094)
- Testing
- Intermittent fasting
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis, Relapsing-Remitting
Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis
The aim of this study is to determine whether prophylactic vaccines recommended are effective and safe in patients with multiple sclerosis(MS) under MS-specific therapy.
- Trial name
- NCT02275741
- Testing
- prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- Dr. med. Micha Loebermann
Relapsing Remitting Multiple Sclerosis
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Interleukin-2 (IL-2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising immunoregulatory drug having the capacity to stimulate regulatory T cells (Tregs).
- Trial name
- MS-IL2 (NCT02424396)
- Testing
- IL2
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Remitting-Relapsing Multiple Sclerosis
TMP001 in Relapsing-remitting Multiple Sclerosis
The purpose of this study is to assess the impact of TMP001 in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT02686788
- Testing
- TMP001
- Where
- 5 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Dr. Frank Behrens
Multiple Sclerosis, Relapsing-Remitting
RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS
A randomized trial of long-term dosage of rituximab in multiple sclerosis
- Trial name
- RIDOSE-MS (NCT03979456)
- Testing
- Rituximab
- Where
- 17 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Karolinska Institutet
Multiple Sclerosis, Relapsing-Remitting
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
The present study aims to assess the adherence to therapy with interferon beta-1a (Rebif®) and at investigating potential factors that are involved in its outcome, in a representative sample of patients with relapsing remitting…
- Trial name
- NCT01112345
- Where
- Greece
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS) - Relapsing-remitting, Mediterranean Diet
Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis
This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HistaMed-MS (NCT07501520)
- Testing
- Low Histamine-Based Modified Mediterranean Diet, Traditional Mediterranean Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people
- Sponsor
- Firat University